Drug Trial Radar · NCT05961007
Evaluation of IBI302 Injection in nAMD or DME
Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
234
Planned (sponsor's estimate)
Start
Nov 18, 2021
Primary completion
Oct 31, 2023
Study completion Apr 30, 2024
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of intravitreal IBI302 in the treatment of subjects with neovascular age-related macular degeneration (only in Phase I) or diabetic macular edema.
Conditions
- Neovascular Age-related Macular Degeneration
- Diabetic Macular Edema
Interventions
Intravitreal injection of IBI302(dose 1)Biological
IBI302(dose 1) intravitreal injection given as protocol
Intravitreal injection of IBI302(dose 2)Biological
IBI302(dose 2) intravitreal injection given as protocol
Intravitreal injection of IBI302(dose 3)Biological
IBI302(dose 3) intravitreal injection given as protocol
Intravitreal injection of AfliberceptDrug
Aflibercept intravitreal injection given as protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of ocular and non-ocular adverse events.Time frame: Up to week 20
- DLT in each groupTime frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.